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YEAR IN CARDIOLOGY SERIES YEAR IN INTERVENTIONAL CARDIOLOGY1497Year in Interventional CardiologySimon R. Dixon, Robert D. Safian
Dixon and Safian reivew more than 100 articles published last year in the field of
interventional cardiology. The highlights are compiled in an outline format with relevant
synopses. This paper will serve as a valuable reference for readers who wish to either explore
certain topics in more detail or simply have a broad overview of major developments.CLINICAL RESEARCH CLINICAL TRIAL1509Targeting LV Lead to Optimal Area Improves Outcomes With CRTFakhar Z. Khan, Mumohan S. Virdee, Christopher R. Palmer, Peter J. Pugh, Denis O’Halloran,
Maros Elsik, Philip A. Read, David Begley, Simon P. Flynn, David P. Dutka
The TARGET study randomized cardiac resynchronization therapy (CRT) patients to a
methodically placed to left ventricular (LV) lead placement or usual care. All patients
underwent baseline speckle tracking 2D radial strain imaging prior to randomization. In the
targeted lead group, the LV lead was positioned to the latest site of peak contraction, whereas
the control patients underwent standard CRT lead placement. In the TARGET group, 70%
of subjects had a 15% reduction in left ventricular systolic volume at 6 months compared to
55% in the control group. This was also associated with improved clinical outcomes.
Compared to standard CRT treatment, the use of baseline speckle tracking to target LV lead
placement yields significantly improved outcomes.Editorial Comment: Jalal K. Ghali, p. 1519PREVENTIVE CARDIOLOGY1521Similar Predictive Value for LDL-C and Other Lipid Markers in the JUPITER TrialSamia Mora, Robert J. Glynn, S. Matthijs Boekholdt, Børge G. Nordestgaard, John J. P. Kastelein,
Paul M. Ridker
Mora and colleagues used data from the JUPITER trial to determine which lipid
measurement predicts the subsequent risk of cardiac events in patients treated with high-dose
statin therapy. Using multivariate Cox models, on-treatment low-density lipoprotein
cholesterol (LDL-C), non–high-density lipoprotein cholesterol (HDL-C), apolipoprotein B,
total/HDL-C, LDL-C/HDL-C, and apolipoprotein B/A-1 all provided similar information
regarding the residual risk. On-treatment triglycerides, however, showed no association with
cardiovascular disease.(continued on page A-22)
APRIL 24, 2012 (continued) A-22c
p
EHEART RHYTHM DISORDERS
1529NonInvasive Programmed Ventricular
Stimulation After VT Ablation Predicts Subsequent RiskDavid S. Frankel, Stavros E. Mountantonakis, Erica S. Zado, Elad Anter, Rupa Bala, Joshua M. Cooper,
Rajat Deo, Sanjay Dixit, Andrew E. Epstein, Fermin C. Garcia, Edward P. Gerstenfeld,
Mathew D. Hutchinson, David Lin, Vickas V. Patel, Michael P. Riley, Melissa R. Robinson,
Wendy S. Tzou, Ralph J. Verdino, David J. Callans, Francis E. Marchlinski
Frankel and colleagues evaluated the ability of noninvasive programmed stimulation (NIPS)
following ventricular tachycardia (VT) ablation to identify patients at high recurrence risk.
132 subjects underwent NIPS through their implantable cardioverter-defibrillator (ICD) a
mean of 3 days after their ablation: 45% had no VT inducible at NIPS, 37% had nonclinical
VT inducible only, and 18% had clinical VT inducible. Two-thirds of patients with inducible
clinical VT at NIPS had arrhythmia recurrence in the next year compared to 20% of those
in whom no VT was inducible. The authors conclude that NIPS should be considered after
VT ablation to identify those at high risk for arrhythmia recurrence.Editorial Comment: Gerhard Hindricks, Christopher Piorkowski, p. 1536CARDIAC IMAGING
1539Coronary Arterial 18F-NaF Uptake on PET Scanning
May Identify Areas of Active Vascular CalcificationMarc R. Dweck, Marcus W.L. Chow, Nikhil V. Joshi, Michelle C. Williams, Charlotte Jones,
Alison M. Fletcher, Hamish Richardson, Audrey White, Graham McKillop, Edwin J.R. van Beek,
Nicholas A. Boon, James H.F. Rudd, David E. Newby
Uptake of 18F-sodium fluoride (18F-NaF), an established positron emission tomography
tracer for bone activity, has also been described in aortic and carotid atheroma where it may
identify areas of active vascular calcification. Dweck et. al. investigated coronary arterial uptake
of 18F-NaF and 18F-fluorodeoxyglucose (18F-FDG). 18F-NAF activity was higher in
patients with coronary atherosclerosis versus controls and correlated with the calcium score,
although 40% of those with scores 1,000 displayed normal uptake. Quantification of
oronary 18F-FDG uptake was hampered by myocardial activity and was not increased in
atients with atherosclerosis versus controls.
ditorial Comment: Richard T. George, p. 1549(continued on page A-24)
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in Vascular Injury and Stent-Induced Flow DisturbanceAaron B. Baker, William J. Gibson, Vijaya B. Kolachalama, Mordechai Golomb, Laura Indolfi,
Christopher Spruell, Eyal Zcharia, Israel Vlodavsky, Elazer R. Edelman
Heparanase degrades heparan sulfate in mammalian cells; heparanase expression is increased
during neointimal hyperplasia and in patients with diabetes. Baker and colleagues investigated
the consequences of heparanase overexpression using a mouse model. In the absence of
vascular injury, wild type and heparanase overexpressing (HPA Tg) mice had similar time to
thrombosis. However, in the presence of vascular injury, the time to thrombosis was
dramatically reduced in HPA Tg mice. Further studies demonstrated markedly increased
thrombosis on stents with blood isolated from HPA Tg mice. These results indicate that
heparanase is a powerful mediator of thrombosis in the context of vascular injury and stent-
induced flow disturbance.FROM AROUND THE WORLD1561Reimbursement Policies and the Practice of Cardiology in GermanyFrank A. Flachskampf, Johannes von Erffa, Christian Seligmann
While in general the practice of cardiology does not differ dramatically between Germany and
the United States, Flachskampf and colleagues explore how reimbursement practices may
disincentivize conservative management of coronary artery disease in Germany. This occurs
because physicians receive a low flat quarterly fee for outpatient cardiology care including
imaging studies. Reimbursement for invasive angiography or percutaneous coronary
intervention is much higher. Similar incentives encourage invasive procedures for inpatients,
and the per capita rates of these procedures are higher in Germany than in other countries.
The authors argue that the current system in Germany financially penalizes conservative
clinical management, de-emphasizes ischemia testing, and encourages invasive procedures.Commentary: Georg Ertl, p. 1566
